BioTime acquires assets of Cell Targeting - MarketLine Financial Deals

BioTime acquires assets of Cell Targeting

BioTime acquires assets of Cell Targeting - MarketLine Financial Deals
BioTime acquires assets of Cell Targeting
Published Jan 28, 2011
2 pages — Published Jan 28, 2011
Price US$ 20.00  |  Buy this Report Now

About This Report

  
Abstract:

BioTime, Inc. has acquired all the assets of Cell Targeting, Inc. (CTI), a biotechnology company conducting research in regenerative medicine.

  
Source:
Document ID
MA48389_110131
Country
Ticker
BTIM=US
Format:
PDF Adobe Acrobat
Buy Now

MarketLine Financial Deals—MarketLine Financial Deals – Identifying and tracking major financial activity across our full scope of company and sector coverage, MarketLine Financial Deals covers mergers & acquisitions, private equity/venture capital backed buyouts, investments, and exits, IPOs and secondary and follow on offerings, and private placements and exits. Additional non-corporate financial deals including partnership agreements, joint ventures, co-development and research, licensing and co-marketing agreements are also available.

About the Author


Cite this Report

  
MLA:
MarketLine Financial Deals. "BioTime acquires assets of Cell Targeting" Jan 28, 2011. Alacra Store. Dec 08, 2016. <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/BioTime-acquires-assets-of-Cell-Targeting-2052-52098>
  
APA:
MarketLine Financial Deals. (2011). BioTime acquires assets of Cell Targeting Jan 28, 2011. New York, NY: Alacra Store. Retrieved Dec 08, 2016 from <http://www.alacrastore.com/storecontent/MarketLine-Financial-Deals/BioTime-acquires-assets-of-Cell-Targeting-2052-52098>
  
US$ 20.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our MarketLine Financial Deals from one place.